Sign In
Buy MRK
$120.78
+1.69 (+1.41%)
At Close: Jun 11, 2026
Merck stock jumps as Keytruda combo trials boost cancer pipeline
02:31pm, Friday, 22'nd May 2026
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend
Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?
12:15pm, Friday, 22'nd May 2026
Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.
Pharma Stock Pops On European Seal of Approval
10:51am, Friday, 22'nd May 2026
Merck (NYSE:MRK) stock is up 5% to trade at $121.75, after the blue-chip pharma giant received the "go ahead" from European officials in regard to its combination of the company's products, Keytruda
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.
10:23am, Friday, 22'nd May 2026
Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.
Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer
09:07am, Friday, 22'nd May 2026
Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
05:06pm, Thursday, 21'st May 2026
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda improved survival rate in patients with advanced lung cancer, meeting the
Moderna, Merck cancer combo cuts melanoma spread risk at five years
05:03pm, Thursday, 21'st May 2026
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a mid-stage trial showe
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?
11:16am, Thursday, 21'st May 2026
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
08:00am, Thursday, 21'st May 2026
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
03:35pm, Wednesday, 20'th May 2026
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims
11:00am, Wednesday, 20'th May 2026
A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commissio
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
12:50pm, Tuesday, 19'th May 2026
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
07:35am, Monday, 18'th May 2026
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
07:28am, Monday, 18'th May 2026
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
